Browse the corpus

©2013 UpToDate ® Print Email Standardized reporting for correlation of cytogenetic and molecular genetic data in acute myeloid leukemia with clinical data Genetic group Subsets Favorable t(8;21)(q22;q22); RUNX1-RUNX1T1 inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Mutated NPM1 without FLT3 -ITD (normal karyotype) Mutated CEBPA (normal karyotype) Intermediate-I* Mutated NPM1 and FLT3 -ITD (normal karyotype) Wild-type NPM1 and FLT3 -ITD (normal karyotype) Wild-type NPM1 without FLT3 -ITD (normal karyotype) Intermediate-II t(9;11)(p22;q23); MLLT3-MLL Cytogenetic abnormalities not classified as favorable or adverse• Adverse inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 t(6;9)(p23;q34); DEK-NUP214 t(v;11)(v;q23); MLL rearranged -5 or del(5q); -7; abnl(17p); complex karyotypeΔ Frequencies, response rates, and outcome measures should be reported by genetic group, and, if sufficient numbers are available, by specific subsets indicated; excluding cases of acute promyelocytic leukemia. AML: acute myeloid leukemia; WHO: World Health Organization. * Includes all AMLs with normal karyotype except for those included in the favorable subgroup. • For most abnormalities, adequate numbers have not been studied to draw firm conclusions regarding their prognostic significance. Δ Three or more chromosome abnormalities in the absence of one of the WHO designated recurring translocations or inversions, that is, t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), inv(3) or t(3;3). This research was originally published in Blood. Döhner, H, Estey, EH, Amadori, S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453. Copyright © 2010 American Society of Hematology.